M. B. M. contributed to data analysis and interpretation, and manuscript writing; J. B. B. contributed to study design, data interpretation, and manuscript writing; and E-J. L. contributed to study design, data collection and interpretation, and manuscript writing.
Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
References
1
Mahévas M,
Moulis G,
Andres E.
et al.
Clinical characteristics, management and outcome of COVID-19-associated immune thrombocytopenia: a French multicentre series. Br J Haematol 2020; 190 (04) e224-e229
4
Moulis G,
Crickx E,
Thomas L.
et al;
French Covigilance COVID-19 Vaccine-ITP Study Group.
De novo and relapsed immune thrombocytopenia after COVID-19 vaccines: results of French safety monitoring. Blood 2022; 139 (16) 2561-2565
5
Rodeghiero F,
Stasi R,
Gernsheimer T.
et al.
Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009; 113 (11) 2386-2393
6
Lee EJ,
Beltrami Moreira M,
Al-Samkari H.
et al.
SARS-CoV-2 vaccination and immune thrombocytopenia in de novo and pre-existing ITP patients. Blood 2022; 139 (10) 1564-1574
8
Crickx E,
Moulis G,
Ebbo M.
et al.
Safety of anti-SARS-CoV-2 vaccination for patients with immune thrombocytopenia. Br J Haematol 2021; 195 (05) 703-705
10
Fattizzo B,
Bortolotti M,
Giannotta JA,
Consonni D,
Cantoni S,
Barcellini W.
Seroconversion to mRNA SARS-CoV-2 vaccines in patients with autoimmune cytopenias and bone marrow failures. Sci Rep 2022; 12 (01) 7743
